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INTRODUCTION
Mammary Analogue Secretory Carcinoma (MASC) of the salivary glands is a recently described pathologic entity of unknown incidence that resembles secretory carcinoma of the breast. Both tumors share the balanced translocation t(12;15) (p13;q25) forming the ETV6-NTRK6 fusion gene which encodes a chimeric tyrosine kinase 1 . Prior to its description, MASC was most likely identified as salivary acinic cell carcinoma (AciCC), mucoepidermoid carcinoma (MEC), cystadenocarcinoma, or other salivary gland tumors; each shares overlapping histological and immunohistochemical features [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 23, 30 . With detection of the translocation by fluorescent in-situ hybridization (FISH), the current gold standard for diagnosis, many cases previously diagnosed as aforementioned salivary gland tumors have been retrospectively reclassified as MASC [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 23, 30 .
There are currently four pediatric case reports in the current literature dating back to 2011 describing patients with MASC [19] [20] [21] 28 . Recent case reports and studies have made efforts to describe the unique cytopathological and clinical characteristics as a means to accurately differentiate and diagnose MASC. Some key features identified include:
• Slow growing, fixed, and painless nodule, often detected incidentally on physical examination 1, 4, 5, 8, 15, 24 • Eosinophilic vacuolated cytoplasm within cystic, tubular, and/or papillary architecture 4, 5, 22, 23 • Secretions that stain positive for periodic acid Schiff (PAS) and are diastase-resistant 1,4,5,22-
26
• Low-grade, pale nuclei, and rare mitotic figures 5, 23 • Positive staining for S-100, mammaglobin, vimentin, cytokeratin 19
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The purpose of this study is to report a rare case of pediatric MASC as well as to review and consolidate the existing literature involving this new salivary gland malignancy within the pediatric population.
METHODS
The institutional review board (IRB) reviewed the included case report and it was determined that no further approval was required. Photo consent was obtained and all patient information was handled in a manner consistent with the Health Insurance Portability and Accountability Act (HIPAA).
We reviewed the clinical records of one child with MASC treated at our tertiary care pediatric hospital. Data collected included basic demographic information, clinical notes, pathology, laboratory and radiologic reports relevant to this study. The patient's medical history including: past medical history, surgical history, and social history were retrieved from the electronic medical record.
A literature review was performed to identify all documented cases of patients with MASC in the pediatric population. A medical librarian was enlisted to employ the search strategy included in eFigure 1 (Supplement 1). Web of Science, Medline, EMBASE, and The Cochrane Library were queried and the resultant articles screened by four independent reviewers.
Only studies that included pediatric cases of MASC were included. Clinical presentation, diagnosis and management, and pathology were collected for each documented case. Furthermore, the patient is disease free at 14 months post-operatively.
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Assessment and Diagnosis
The surgical pathology of the left superficial parotidectomy and left level II neck dissection specimens prominently demonstrated a well demarcated but unencapsulated, yellowtan to red-brown, diffusely degenerative mass that has overall dimensions of 2.8 x 2.5 x 2 cm. The constellation of these findings was consistent with the diagnosis of mammary analogue secretory carcinoma (MASC) of the parotid gland.
Review of Literature
The initial database query and resulted in a total of 35 articles as demonstrated in the prisma flow diagram in eFigure 1 (Supplement 1). Four independent reviewers screened the full text articles for pediatric cases of MASC and 11 articles were deemed relevant to this study. One paper was excluded because the pediatric case could not be distinguished from the adult cases reported. The 10 remaining papers included a total of 4 pediatric case reports, 19-21,28 5 retrospective reviews 8, 9, 12, 17, 18 and 1 editoral letter 6 of pediatric MASC, evaluating or reporting a total of 11 pediatric patients, which are displayed in Table 1 archives, previous diagnoses included 3 patients 6, 12, 18 with AciCC, 1 with MEC, 1 with pleomorphic adenoma 9 , 1 case with MASC 17 and 1 patient was not specified 8 .
Clinical Presentation
The 11 pediatric patients ranged in age of 10-17 years with a median age of 15 years, and a female-to-male ratio of 1:1.2. The mean size of the tumor, reported in 10 of 11 patients, was 2.41 cm (range 1.0-3.8 cm) 6, 8, 9, 12, [18] [19] [20] [21] 28 . The most common clinical presentation, in the 4 case reports, was a slowly enlarging, fixed, and painless mass, often detected incidentally on physical examination. Of 11 pediatric patients included in this analysis, 9 of the tumors were located in the parotid gland 9, 12, 17, 18, [19] [20] [21] 28 , one was reported in the submandibular gland 8 and one in the upper lip 6 .
Assessment and Diagnosis
Work-up described in the 4 case reports included combinations of magnetic resonance imaging (MRI), computerized tomography (CT) and/or FNA; 2 cases utilized MRI 19, 21 , one utilized CT imaging 28 , and one utilized both CT imaging and MRI 20 . MRI findings were described as: well-circumscribed lesion with internal T2 hyper-intensity and intermediate T1
signal with a dependent fluid 19 , mildly enhancing preauricular subcutaneous soft tissue mass 20 , and a heterogeneously enhancing tumor at the superficial parotid lobe 21 . CT scan findings were M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 described as a 2 x 2 cm fluid collection with rim enhancement in the anterior left parotid 20 . FNA was utilized in two cases 19, 20 . One of which was non-diagnostic 19 and the other was suggestive of salivary neoplasm 20 .
All 4 case reports and 6 re-review cases reported histology and immunohistochemical staining results, individual findings reported in Table 1 . The tumors were grossly described as a yellow-brown to tan, well-demarcated, unencapsulated cystic mass [19] [20] [21] 28 . 
Treatment
All cases of MASC were surgically resected. Surgical intervention and adjuvant therapy was discussed only in the 4 case reports [19] [20] [21] 28 . Two cases described superficial parotidectomy with FN dissection 19, 20 , one of which required sacrifice of the FN 20 , one case described a total parotidectomy with preservation of the FN and right selective neck dissection with exploration of M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 9 preauricular, level I, and level II lymph nodes 28 , and one case simply reported a "tumor excision" 21 . In all cases, post-operative radiation therapy was not deemed necessary.
Prognosis
Long-term disease specific outcomes are limited due to disease incidence and reporting as well as the relatively new identification of MASC as a distinct pathology. One study reports a patient with six recurrences in a 15-year period 9 . No evidence of disease was reported in 5 patients 9, 12,18,21,28 , however duration of follow-up ranging from 8 months to 10 years, was only reported in 3 patients 12,21,28 .
DISCUSSION
The ETV6-NTRK3 fusion gene is a result of the balanced translocation t(12;15)(p13;q25); the fusion gene encodes for a chimeric tyrosine kinase. 1 MASC is a predominantly adult neoplasm, diagnosed at a median age of 45, and with a predilection for the parotid gland. 4, 5 Many of the published cases of MASC are re-reviewed salivary tumors found retrospectively to harbor the t(12;15)(p13;q25) translocation. In the largest of these reviews, which analyze both adult and pediatric patients, tumors previously diagnosed as other salivary gland tumors were found to represent MASC 4, 12, 23, 30 . Of 546 total cases of salivary gland carcinomas re-reviewed in these studies, 34 (6.2%) were found to be MASC. Of those that reported information on previous diagnosis 4, 12, 30 (n=21): 15 were AciCC, 2 MEC, 2 Adenocarcinoma, 1 Cystadenocarcinoma, and 1 Salivary duct carcinoma.
The MASC diagnosis is exceedingly rare in the pediatric population with 11 cases reported in the literature. There is a slight male predilection with a female-to-male ratio of 1:1.2, There is insufficient data on patient outcomes to base clinical management. Optimal management is therefore currently unknown but given that MASC was likely previously treated as AciCC, managing MASC like AciCC is logical until more data is obtained on MASC.
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Additional research and long-term follow-up are necessary to determine the prognosis and clinical behavior of MASC in the pediatric population. Overall, MASC seems to have survival outcomes comparable to AciCC in the adult population. 4 The reported 5-year survival for AciCC being 90%, but 10-and 20-year survivals are 83% and 67%, respectively. 29 Data on disease outcomes in large cohorts of AciCC patients are well known, but complicated by the probable inclusion of a sub-group of patients with a diagnosis of MASC.
As awareness of this recently described malignancy increases and more cases are 
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